Compare YSXT & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSXT | KPTI |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8M | 172.6M |
| IPO Year | N/A | 2013 |
| Metric | YSXT | KPTI |
|---|---|---|
| Price | $1.34 | $8.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $17.50 |
| AVG Volume (30 Days) | 330.1K | ★ 620.8K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $146,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $46.62 |
| P/E Ratio | $5.57 | ★ N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $1.03 | $3.51 |
| 52 Week High | $9.90 | $10.99 |
| Indicator | YSXT | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 58.02 | 49.70 |
| Support Level | $1.08 | $5.60 |
| Resistance Level | $1.51 | $8.95 |
| Average True Range (ATR) | 0.15 | 0.75 |
| MACD | 0.01 | -0.18 |
| Stochastic Oscillator | 53.26 | 40.07 |
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).